GE HealthCare (GEHC) announced a distribution and services agreement with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography imaging solutions to hospitals and outpatient practices throughout the U.S. Through this agreement, GE HealthCare aims to bring Flyrcado injection, its novel cardiac PET imaging agent, to patients nationwide, including private cardiology practices and office and hospital imaging settings, expanding the reach of cardiac PET for the evaluation of known or suspected coronary artery disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Cooperman’s Omega bought Atlas Energy and ArriVent in Q2
- GE HealthCare price target raised to $93 from $89 at Citi
- Cautious Outlook for GE Healthcare Technologies: Hold Rating Maintained Amid Market Expectations and Trade Uncertainties
- GE HealthCare Reports Strong Q2 2025 Performance
- GE Healthcare’s Earnings Call Highlights Growth Amid Challenges